Polycystic ovary syndrome (PCOS) occurs when there is an overproduction of androgens from the ovaries. PCOS can form cysts around the ovaries due to the lack of hormones needed for ovulation. PCOS affects around 1 in 10 women of childbearing age, with up to 70% of women being undiagnosed globally.1 The specific cause of PCOS is not fully understood and remains a subject of ongoing research. PCOS can lead to other complications including cancer, diabetes, infertility, hypertension, and cardiovascular disease.2
PCOS can be managed with nonpharmacological and/or pharmacological interventions, depending on the patient's preference and other patient-specific factors. PCOS is an endocrine disorder associated with increased androgen levels, obesity, insulin resistance, irregular menstrual cycles, and other hormonal imbalances. Elevated levels of gonadotropin releasing hormone and luteinizing hormone also contribute to PCOS.3 Symptoms can include hirsutism, acne, alopecia, weight gain, skin tags, acanthosis nigricans, and pelvic pain.3
PCOS can be diagnosed through a combination of physical exams, such as pelvic exam or pelvic sonogram, and blood tests that evaluate levels of follicular stimulating hormone, androgen, and testosterone.4 PCOS is most prevalent among women ages 15 to 44 years, and is the leading cause of anovulation and infertility.3 PCOS not only affects a woman’s physical health, but it can also be mentally and financially burdensome, due to the complexity of the condition. As health care workers on the front lines, pharmacists can play an important role in the diagnosis, management, and disease state education of PCOS, in hopes of improving patient outcomes and overall quality of life.
Epidemiology and Etiology
According to the National Institute of Health, approximately 5 million women (1 in 10 women of childbearing age) in the United States are affected by PCOS, making it one of the most common endocrine disorders among women of reproductive age. With varying estimates due to differences in diagnostic criteria, PCOS affects women of all ethnic backgrounds, with some studies suggesting variations in prevalence and clinical features among different populations. As reported in 2017, it was found that Hispanic women with PCOS presented with a higher degree of hyperandrogenism and metabolic aberrations as compared to non-Hispanic women.5 Despite these facts, its origin is still largely misunderstood and underdiagnosed.5,6
PCOS is characterized by hyperandrogenism, which is partly due to increased ovarian and adrenal androgen production. Insulin resistance and compensatory hyperinsulinemia further exacerbate hyperandrogenism by increasing ovarian androgen production and decreasing sex hormone-binding globulin levels, leading to increased free androgens.7 Insulin resistance also progresses patients' onset of diabetes and metabolic complications. Lifestyle factors, such as diet and physical activity, also play a role in the development and severity of PCOS. Obesity, particularly central obesity, is commonly associated with PCOS and exacerbates insulin resistance and hyperandrogenism.8
Diagnosis and Clinical Presentation
The diagnostic criteria and classification of PCOS have evolved, as more information is learned about the condition.5,9,10 In 2003, a workshop in Rotterdam formulated a new diagnostic criterion named Rotterdam criteria, which required the presence of 2 conditions out of the following 3: oligomenorrhea/anovulation, clinical/biochemical hyperandrogenism, and polycystic ovaries (≥12 follicles in each ovary measuring 2-9 mm). In 2006, the revised Androgen Excess Society criteria required the specific presence of clinical/biochemical hyperandrogenism in combination with either oligo anovulation or polycystic ovaries.5,10 The variation in diagnostic criteria adds to the complexity of this disease state in terms of its identification and management.
PCOS can be diagnosed in adolescents soon after menarche and up to menopause. The criteria for diagnosis in adolescents require hyperandrogenism and irregular cycles.8 Hallmark signs and symptoms of PCOS include anovulation, hyperandrogenism, and polycystic ovaries.5,6,9,10 Other major manifestations of PCOS include luteinizing hormone hypersecretion, metabolic disturbances, hyperinsulinemia, insulin resistance, glucose intolerance, dyslipidemia, alopecia, hirsutism, and acne.5,6,9,10 Women with PCOS are also at increased risk for several comorbidities, including type 2 diabetes, metabolic syndrome, cardiovascular disease, and endometrial cancer.5-7,9,10 Additionally, PCOS increases the risk of further complications including infertility, pregnancy complications, depression, and anxiety.5
Pharmacological and Nonpharmacological Management
The management of PCOS involves a tailored approach depending on the patient's preferences, such as fertility, menstrual regulation, weight reduction, or relief from hyperandrogenic symptoms like acne, hirsutism, or androgenic alopecia. There is no single ideal treatment or cure for PCOS, so therapy is often based on symptomatic relief. The need to improve the clinical and therapeutic management of PCOS patients has become increasingly evident in the last decade. Many treatment possibilities exist to correct the severity of clinical symptoms of PCOS, but no current gold standard or FDA-approved drugs have been identified for the treatment and management of these patients. Below, we will cover a few of the nonpharmacological and pharmacological treatment options for managing symptoms of PCOS.